TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protara Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.33+0.01 (+0.43%)
Close on Oct 19, 2026
- Market cap
- $142.15M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -56.0% | -34.5% | -31.6% | |
| Return on assets | -51.4% | -33.2% | -29.4% | |
| Current ratio | 8.42 | 58.13 | 14.58 | |
| Diluted shares | 0M | 7M | 43M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Protara Therapeutics generated $190.69M from operations and spent $1.33M on capital expenditure, dividends and share buybacks. 69% of that went back into the business.
Generated
$190.69M
Used
$1.33M
Capital expenditure$918.00K69%Dividends$00%Share buybacks$409.00K31%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$57.44M
- Cash generatingOperating cash flow above zero-$56.37M
- Return on assets improvedROA up on the prior year-56.5% → -31.7%
- Earnings backed by cashOperating cash flow above net income-$56.37M vs -$57.44M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose15.71 → 14.58
- No dilutionShare count did not rise21M → 43M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –